Shanghai Junshi Biosciences Co (OTCPK:SHJBF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Shanghai Junshi Biosciences Co EBITDA Margin % Related Terms
Shanghai Junshi Biosciences Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Junshi Biosciences Co EBITDA Margin % Chart
SHJBF vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Junshi Biosciences Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Shanghai Junshi Biosciences Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Junshi Biosciences Co (SHJBF) has a EBITDA Margin % of -34.93% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanghai Junshi Biosciences Co and its competitors. According to the industry distribution chart, Shanghai Junshi Biosciences Co ranks #422 out of 945 companies in the Biotechnology industry, placing it in the top 44.7%.
Is Shanghai Junshi Biosciences Co's EBITDA Margin % too high?
Shanghai Junshi Biosciences Co's current EBITDA Margin % is -34.93%. Based on the distribution chart, Shanghai Junshi Biosciences Co ranks #422 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Shanghai Junshi Biosciences Co has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Shanghai Junshi Biosciences Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Junshi Biosciences Co ranks #422 out of 945 companies for EBITDA Margin %. This puts Shanghai Junshi Biosciences Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanghai Junshi Biosciences Co and its competitors. Shanghai Junshi Biosciences Co's current EBITDA Margin % is -34.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Junshi Biosciences Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Junshi Biosciences Co (SHJBF) is currently considered Possible Value Trap. The stock's GF Value™ is $6.14, compared to a current price of $3.35 — trading 45.4% below its estimated fair value. The current EBITDA Margin % is -34.93%. Shanghai Junshi Biosciences Co's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Shanghai Junshi Biosciences Co (SHJBF), the current EBITDA Margin % is -34.93% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Junshi Biosciences Co (SHJBF) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Junshi Biosciences Co stock appears to be undervalued.
The current stock price of $3.35 is trading 45.4% below its estimated GF Value™ of $6.14.
GuruFocus considers Shanghai Junshi Biosciences Co to be Possible Value Trap.
Key valuation signals for SHJBF:
EBITDA Margin %: -34.93%
GF Value™: $6.14 vs. price of $3.35 (45.4% below fair value)
No single metric tells the full story. See the SHJBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Junshi Biosciences Co Business Description
Shanghai Junshi Biosciences Co Ltd is mainly involved in the discovery, development, and commercialisation of therapeutic drugs. It focuses on the development and commercialization of several kinds of drugs, ranging from monoclonal antibodies to various drug modalities, including small molecules, ADCs, bi-specific or multi-specific antibodies, fusion proteins, nucleic acid drugs, and vaccines, as well as the exploration of next-generation therapies, including those for cancer and autoimmune diseases. The Group's portfolio includes commercialized drugs such as Tuoyi, Junmaikang, Mindewei, and Junshida, as well as products in clinical studies or in the marketing application stage. Geographically, it derives maximum revenue from Mainland China, and the rest from USA, India, and other markets.
66GF Score
Get the complete analysis for SHJBF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHJBF has been successfully added to your 
